A Long-Term Study for Extended BMN 701 Treatment of Patients With Pompe Disease Who Have Completed BMN 701 Studies
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2016
At a glance
- Drugs Reveglucosidase alfa (Primary)
- Indications Glycogen storage disease type II
- Focus Adverse reactions
- Sponsors BioMarin Pharmaceutical
- 21 Jul 2016 The trial was completed in Germany (end date: 2016-06-22).
- 25 Feb 2015 Planned End Date changed from 1 Sep 2016 to 1 Sep 2018 as reported by ClinicalTrials.gov record.
- 25 Feb 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2018 as reported by ClinicalTrials.gov record.